Pharsight

Application	Filing Date	Opposition Party	Legal Status

EP10183693A	2017-07-12	Accord Healthcare Ltd	Opposition rejected
EP10183693A	2017-07-12	Teva Pharmaceutical Industries Ltd	Opposition rejected
EP10183693A	2017-07-11	Zentiva k.s.	Opposition rejected
EP03763695A	2012-09-28	Accord Healthcare Ltd	Revoked
EP03763695A	2012-09-27	Zentiva k.s.	Revoked

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8841446	BAYER HLTHCARE	Medicaments containing vardenafil hydrochloride trihydrate	Jul, 2023 (2 months ago)
US8273876	BAYER HLTHCARE	Medicaments containing vardenafil hydrochloride trihydrate	Jul, 2027 (3 years from now)

Levitra is owned by Bayer Hlthcare.

Levitra contains Vardenafil Hydrochloride.

Levitra has a total of 2 drug patents out of which 1 drug patent has expired.

Expired drug patents of Levitra are:

Levitra was authorised for market use on 19 August, 2003.

Levitra is available in tablet;oral dosage forms.

Levitra can be used as treatement of erectiile dysfunction by administering a film-coated tablet.

The generics of Levitra are possible to be released after 23 July, 2027.

Market Authorisation Date: 19 August, 2003

Treatment: Treatement of erectiile dysfunction by administering a film-coated tablet

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
2.5 mg	04 Sep, 2009	1	03 May, 2012	31 Oct, 2018	Deferred
5 mg and 10 mg	10 Jul, 2009	1	03 May, 2012	31 Oct, 2018	Deferred
20 mg	05 Mar, 2009	1	03 May, 2012	31 Oct, 2018	Deferred

LEVITRA family patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic